{
    "clinical_study": {
        "@rank": "55378", 
        "arm_group": [
            {
                "arm_group_label": "THS 2.2/CC", 
                "arm_group_type": "Active Comparator", 
                "description": "Subjects will be randomized to receive either THS 2.2 followed by CC, or CC followed by THS 2.2"
            }, 
            {
                "arm_group_label": "THS 2.2/Nicotine nasal spray (NNS)", 
                "arm_group_type": "Active Comparator", 
                "description": "Subjects will be randomized to receive either THS 2.2 followed by NNS, or NNS followed by THS 2.2"
            }
        ], 
        "brief_summary": {
            "textblock": "The overall goal of the study is to evaluate the pharmacokinetic (PK) profile (rate and the\n      amount of nicotine absorbed) following a single use of the THS 2.2 compared to the PK\n      profiles from a single use of a conventional cigarette (CC) and from a single use of\n      nicotine nasal spray."
        }, 
        "brief_title": "Nicotine Pharmacokinetic Profile and Safety of The Tobacco Heating System 2.2 (THS 2.2)", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "condition": "Smoking", 
        "condition_browse": {
            "mesh_term": "Smoking"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject is Caucasian\n\n          -  Smoking, healthy subject as judged by the Investigator.\n\n          -  Subject smokes at least 10 commercially available non menthol CCs per day (no brand\n             restrictions) for the last 4 weeks, based on self reporting.\n\n          -  Subject has smoked for at least the last 3 consecutive years.\n\n          -  Subject does not plan to quit smoking in the next 3 months.\n\n        Exclusion Criteria:\n\n          -  As per Investigator judgment, the subject cannot participate in the study for any\n             reason (e.g., medical, psychiatric, and/or social reason).\n\n          -  The subject has received medication within 14 days or within 5 half-lives of a drug\n             (whichever is longer) which has an impact on CYP2A6 activity.\n\n          -  For women: subject is pregnant or is breast feeding.\n\n          -  For women only: Subject does not agree to use an acceptable method of effective\n             contraception."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "62", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01967732", 
            "org_study_id": "ZRHR-PK-01-EU", 
            "secondary_id": [
                "ZRHR-PK-01-EU", 
                "2013-003097-27"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "THS 2.2/CC", 
                    "THS 2.2/Nicotine nasal spray (NNS)"
                ], 
                "description": "Single use of THS 2.2", 
                "intervention_name": "THS 2.2", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "THS 2.2/CC", 
                "description": "Single use of subject's own CC", 
                "intervention_name": "CC", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "THS 2.2/Nicotine nasal spray (NNS)", 
                "description": "Single administration of 1 mg of nicotine", 
                "intervention_name": "NNS", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Nicotine", 
                "Nicotine polacrilex"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Smoking", 
            "Nicotine absorption", 
            "Modified risk tobacco product", 
            "Conventional cigarette", 
            "Nicotine replacement therapy: nasal spray"
        ], 
        "lastchanged_date": "February 19, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Belfast", 
                    "country": "United Kingdom", 
                    "zip": "BT9 6AD"
                }, 
                "name": "Celerion GB Ltd, 22-24 Lisburn Road"
            }
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Single-centre, Open-label, Randomized, Controlled, Crossover Study to Investigate the Nicotine Pharmacokinetic Profile and Safety of THS 2.2 Following Single Use in Smoking, Healthy Subjects Compared to Conventional Cigarettes and Nicotine Nasal Spray", 
        "overall_official": [
            {
                "affiliation": "Celerion GB Ltd.", 
                "last_name": "Adrian Johnston Stewart, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Philip Morris Products S.A.", 
                "last_name": "Christelle Haziza, PhD", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "United Kingdom: Office for Research Ethics Committees Northern Ireland (HSC REC 1 )", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "To evaluate the rate and amount of nicotine absorption from THS 2.2 relative to CC, following a single use of THS 2.2 and CC.", 
            "measure": "Nicotine maximum plasma concentration (Cmax) and area under the nicotine concentration-time curve from start of product use to time of last quantifiable concentration [AUC(0-last)]", 
            "safety_issue": "No", 
            "time_frame": "1 day"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01967732"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Philip Morris Products S.A.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Philip Morris Products S.A.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}